Literature DB >> 32081645

Surveillance systems for healthcare-associated infection in high and upper-middle income countries: A scoping review.

Saho Takaya1, Kayoko Hayakawa2, Nobuaki Matsunaga3, Yuki Moriyama4, Yuichi Katanami4, Taichi Tajima3, Chika Tanaka3, Yuki Kimura3, Sho Saito4, Yoshiki Kusama3, Shinichiro Morioka4, Yumiko Fujitomo3, Norio Ohmagari2.   

Abstract

BACKGROUND: Healthcare-associated infection (HAI) surveillance is useful for improved infection control. To understand the current HAI surveillance systems (HAISS) trend globally, a scoping review was performed.
MATERIALS AND METHODS: The search strategy included academic literature review, Google search, and questionnaires by the Embassies of Japan (registration number: UMIN000036035). Eighty-two high and 56 upper-middle income countries defined by country income classification for the World Bank were targeted. The following information was reviewed: name of the system, official website, languages used in the official website, foundation year, operating body, survey type (prevalence or incidence), reporting periodicity, mode of participation (mandatory or voluntary), targeted medical facilities, targeted HAIs and definitions, targeted antimicrobial resistant pathogens, and parameters. Online accessibility of the official websites of the SS was assessed through Google search. RESULTS AND
CONCLUSION: Forty-two (30.4%) countries (35 [42.7%] high and 7 [12.5%] upper-middle income countries) had national HAISS. Most systems operated on a voluntary basis, monitored HAI incidence, and used the Center for Disease Control and Prevention definitions. Methicillin-resistant Staphylococcus aureus, surgical site infection, and catheter-related blood stream infection were most commonly monitored. Surveillance for device-associated infections was implemented mainly in intensive care units. Thirty-five countries had at least one official website on their systems, while 7 (20.0%) were identified in the top 30 Google search hits, in English. Approximately half of the academic articles identified through PubMed were from three English-speaking countries. The feasibility and benefits of standardization of the HAI surveillance criteria and efficient feedback methods are future considerations.
Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Healthcare-associated infection; Hospital-acquired infection; Infection control; Nosocomial infection; Surveillance

Year:  2020        PMID: 32081645     DOI: 10.1016/j.jiac.2020.01.001

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  4 in total

1.  Association between the frequency of surgeries for video-assisted thoracic surgery and the incidence of consequent surgical site infections: a retrospective observational study based on national surveillance data.

Authors:  Toshiki Kajihara; Koji Yahara; Aki Hirabayashi; Hitomi Kurosu; Motoyuki Sugai; Keigo Shibayama
Journal:  BMC Infect Dis       Date:  2021-04-17       Impact factor: 3.090

2.  Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections.

Authors:  Mark H Wilcox; Matthew Dryden
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

3.  Methicillin-Resistant Staphylococcus aureus (MRSA) Clonal Replacement in a Malaysian Teaching Hospital: Findings from an Eight-Year Interval Molecular Surveillance.

Authors:  Mohd Azrul Hisham Ismail; Norhidayah Kamarudin; Muttaqillah Najihan Abdul Samat; Raja Mohd Fadhil Raja Abdul Rahman; Saberi Saimun; Toh Leong Tan; Hui-Min Neoh
Journal:  Antibiotics (Basel)       Date:  2021-03-19

4.  Analysis of Continuous Prevalence Survey of Healthcare-Associated Infections Based on the Real-Time Monitoring System in 2018 in Shandong in China.

Authors:  Jian Sun; Wen Qin; Lei Jia; Zhen Sun; Hua Xu; Yiyi Hui; Anman Gu; Weiguang Li
Journal:  Biomed Res Int       Date:  2021-06-11       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.